se of Natalizumab in patients with Multiple Sclerosis
- Conditions
- Quality of life
- Registration Number
- RBR-6jhtvfy
- Lead Sponsor
- Faculdade de Ciências Farmacêuticas, Alimentos e Nutrição da Universidade Federal de Mato Grosso do Sul
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot yet recruiting
- Sex
- Not specified
- Target Recruitment
- Not specified
Inclusion Criteria
Patients diagnosed with Multiple Sclerosis, according to the 10th edition of the International Code of Diseases (ICD 10), classified as G35, diagnosed according to revised and adapted McDonalds criteria will be included in the research; of both sexes; aged over 18 years; who have been on natalizumab treatment for at least 3 months, presenting at least one Expanded Disability Status Scale (EDSS) assessment prior to the use of natalizumab and a subsequent assessment
Exclusion Criteria
Individuals with cognitive alterations that make it difficult to remember facts related to their disease and to understand the research will be excluded, as well as those who do not meet the inclusion criteria
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Evaluate the clinical effectiveness of natalizumab in patients with multiple sclerosis by checking the annualized relapse rate, presence of neurological disability progression, rate of disease progression, presence of new lesions in brain and spinal ressonance
- Secondary Outcome Measures
Name Time Method